Abstract | BACKGROUND: OBJECTIVE: METHODS: Observational, multicenter and retrospective study on a case series of patients with moderate-to-severe ulcerative colitis under adalimumab therapy. The variables analyzed were: demographic data, previous infliximab status, concomitant drugs, the Montreal Classification, disease activity (Mayo score) at weeks 0, 8, 26 and 52, or until the last follow-up. Clinical remission was defined as a partial Mayo score ≤2 and Last observation carried forward (LOCF) and Non responder imputation (NRI) analysis were used. RESULTS: Thirty-six patients were included in the study. With LOCF analysis, remission rates at weeks 8, 26 e 52 were of 41.7%, 47.2% and 47.2%, respectively. With NRI analysis, remission rates at weeks 8, 26 and 52 were of 41.7%, 41.7% and 27.8%, respectively. CONCLUSION:
Adalimumab was effective in the treatment of moderate-to-severe ulcerative colitis. Clinical remission was observed in approximately 40% of the patients at weeks 8 and 26, and in almost a quarter of the patients after 1 year of follow up.
|
Authors | Patrícia Zacharias, Aderson Omar Mourão Cintra Damião, Antonio Carlos Moraes, Fábio Vieira Teixeira, Juliano Coelho Ludvig, Rodrigo Bremer Nones, Rogerio Saad-Hossne, Ligia Yukie Sassaki, Rosemary Pereira Lino da Silva, Luiza Facchin, Marcia Olandoski, Paulo Gustavo Kotze |
Journal | Arquivos de gastroenterologia
(Arq Gastroenterol)
Vol. 54
Issue 4
Pg. 321-327
(Dec 2017)
ISSN: 1678-4219 [Electronic] Brazil |
PMID | 28977114
(Publication Type: Journal Article, Multicenter Study, Observational Study)
|
Chemical References |
- Anti-Inflammatory Agents
- Antibodies, Monoclonal, Humanized
- Adalimumab
|
Topics |
- Adalimumab
(therapeutic use)
- Adolescent
- Adult
- Aged
- Anti-Inflammatory Agents
(therapeutic use)
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Colitis, Ulcerative
(drug therapy)
- Female
- Humans
- Longitudinal Studies
- Male
- Middle Aged
- Retrospective Studies
- Severity of Illness Index
- Treatment Outcome
- Young Adult
|